New Zealand Professional Investment Services Firm

Forsyth Barr

We are proud to be a New Zealand owned firm, with 21 offices throughout the country and over 300 employees. We assist personal, institutional and corporate clients providing a full range of investment services.

Forsyth Barr is a foundation New Zealand Exchange firm (NZX) and accredited market participant. We have been confirmed by the Financial Markets Authority as a Qualifying Financial Entity (QFE).

Research is the cornerstone of our advice. We have one of New Zealand's leading teams of analysts. Our global affiliations ensure comprehensive research coverage of all major investment markets.

New Zealand Professional Investment Services Firm, Forsyth Barr

Equity Bottom-Up

<ul><li>AFT Pharmaceuticals (AFT) has today announced US FDA approval of its rapid release tablet form of Maxigesic, which is step one in the process for AFT</li><li>The next steps are (1) finalising a licensing partner, and (2) commercialising sales</li><li>AFT appears advanced on this process and has “held talks with potential US licensees for the medicine and are evaluating US market entry plans to maximise its commercial potential.”</li></ul>

AFT Pharmaceuticals (AFT) has today announced US FDA approval of its rapid release tablet form of Maxigesic, which is step one in the process for AFTThe next steps are (1) finalising a licensing partner, and (2) commercialising salesAFT appears advanced on this process and has “held talks with potential US licensees for the medicine and are evaluating US market entry plans to maximise its commercial potential.”

AFT Pharmaceuticals (AFT): Maxigesic Rapid US Tablet Approval